BRIEF published on 04/08/2025 at 07:51, 1 year 5 months ago GenSight Biologics Dépose son Document d’Enregistrement Universel 2024 AMF Thérapie Génique Document D'enregistrement GenSight Biologics Rétine
BRIEF published on 04/08/2025 at 07:51, 1 year 5 months ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
BRIEF published on 04/08/2025 at 07:48, 1 year 5 months ago GenSight Biologics Files 2024 Universal Registration Document Universal Registration Document GenSight Biologics Gene Therapies Retinal Diseases Financial Report 2024
BRIEF published on 04/08/2025 at 07:48, 1 year 5 months ago GenSight Biologics dépose son document d'enregistrement universel 2024 Document D'Enregistrement Universel GenSight Biologics Thérapies Géniques Maladies De La Rétine Rapport Financier 2024
PRESS RELEASE published on 04/08/2025 at 07:46, 1 year 5 months ago INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS GenSight Biologics met à disposition son Document d'Enregistrement Universel 2024 pour consultation en ligne Document D'Enregistrement Universel GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 04/08/2025 at 07:43, 1 year 5 months ago INSIDE INFORMATION / OTHER NEWS RELEASES GenSight Biologics announces the filing of its 2024 Universal Registration Document with the French market authority, including financial reports and corporate governance details GenSight Biologics Gene Therapies Retinal Neurodegenerative Diseases 2024 Universal Registration Document Central Nervous System Disorders
BRIEF published on 04/07/2025 at 20:19, 1 year 5 months ago GenSight Biologics Financial and Business Update Fundraising Clinical Trials Gene Therapy Financial Update GenSight Biologics
BRIEF published on 04/07/2025 at 20:19, 1 year 5 months ago Mise à jour financière et commerciale de GenSight Biologics Essais Cliniques Thérapie Génique Mise À Jour Financière Collecte De Fonds GenSight Biologics
PRESS RELEASE published on 04/07/2025 at 20:14, 1 year 5 months ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and business update as of March 31, 2025. Discussions with French agency progressing. Fundraising planned for Phase III trial and marketing advancement Business Update Cash Position Fundraising Activities GenSight Biologics RECOVER Phase III Trial
PRESS RELEASE published on 04/07/2025 at 20:14, 1 year 5 months ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation de trésorerie au 31 mars 2025, annonce des activités de levées de fonds pour prolonger l'horizon de trésorerie et fait le point sur ses activités Trésorerie Essai Clinique GenSight Biologics Thérapies Géniques Levées De Fonds
Published on 09/10/2026 at 22:25, 5 hours 3 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 12 hours 8 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 12 hours 28 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 12 hours 51 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 3 hours 22 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 3 hours 26 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 4 hours 48 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 5 hours 17 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 5 hours 20 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 7 hours 58 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 7 hours 58 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 9 hours 18 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 9 hours 43 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 9 hours 45 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
